One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

By sjmartinez • October 23, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Oct 5;77(7):941-949. doi: 10.1093/cid/ciad342. PMID: 37279602; PMCID: PMC10552586.

Tags: camostat, covid-19, Harbor UCLA, Infectious Diseases, outpatient, phase, Publications, SARS-CoV-2

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

Effect of colchicine on progression of known coronary atherosclerosis in patients with stable coronary artery disease: EKSTROM randomized placebo controlled trial

Budoff MJ, Bhandari M, Iskander B, Ghanem AK, Kinninger A, Stark J, Garikapati V, Chilukuri S, Hankil V, Krishnan S, Punnanithinont N, Ichikawa K, Kambalapalli[...]